Trade Champions Oncology, Inc. - CSBR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.48 |
| Open | 10.35 |
| 1-Year Change | 81.26% |
| Day's Range | 10.01 - 10.55 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 10.15 | -0.09 | -0.88% | 10.24 | 10.60 | 10.01 |
| Feb 20, 2025 | 10.48 | -0.05 | -0.47% | 10.53 | 10.89 | 10.38 |
| Feb 19, 2025 | 10.56 | 0.12 | 1.15% | 10.44 | 10.82 | 10.44 |
| Feb 18, 2025 | 10.53 | -0.27 | -2.50% | 10.80 | 10.94 | 10.26 |
| Feb 14, 2025 | 10.68 | 0.04 | 0.38% | 10.64 | 11.21 | 10.48 |
| Feb 13, 2025 | 10.80 | -0.09 | -0.83% | 10.89 | 10.94 | 10.27 |
| Feb 12, 2025 | 10.78 | 0.34 | 3.26% | 10.44 | 10.92 | 10.39 |
| Feb 11, 2025 | 10.39 | -0.99 | -8.70% | 11.38 | 11.38 | 10.25 |
| Feb 10, 2025 | 11.36 | 0.57 | 5.28% | 10.79 | 11.85 | 10.49 |
| Feb 7, 2025 | 10.99 | 0.82 | 8.06% | 10.17 | 11.72 | 10.17 |
| Feb 6, 2025 | 10.62 | -0.14 | -1.30% | 10.76 | 10.88 | 10.09 |
| Feb 5, 2025 | 11.01 | 0.79 | 7.73% | 10.22 | 11.34 | 10.22 |
| Feb 4, 2025 | 10.75 | 0.76 | 7.61% | 9.99 | 10.93 | 9.99 |
| Feb 3, 2025 | 9.99 | -0.19 | -1.87% | 10.18 | 10.28 | 9.27 |
| Jan 31, 2025 | 10.97 | 0.69 | 6.71% | 10.28 | 10.97 | 9.86 |
| Jan 30, 2025 | 10.49 | -0.62 | -5.58% | 11.11 | 11.24 | 10.05 |
| Jan 29, 2025 | 10.88 | 0.38 | 3.62% | 10.50 | 11.20 | 10.50 |
| Jan 28, 2025 | 10.56 | -0.93 | -8.09% | 11.49 | 11.57 | 10.56 |
| Jan 27, 2025 | 11.50 | 1.07 | 10.26% | 10.43 | 11.59 | 10.43 |
| Jan 24, 2025 | 11.53 | 0.39 | 3.50% | 11.14 | 11.57 | 11.14 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Champions Oncology, Inc. Company profile
About Champions Oncology Inc
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Champions Oncology Inc revenues increased 19% to $36.2M. Net income decreased 14% to $892K. Revenues reflect Pharmacology services segment increase of 66% to $34.5M, Other segment increase from $101K to $1.7M. Net income was offset by research and development increase of 32% to $6.8M (expense), general and administratiojn increase of 32% to $5.9M (expense).
Equity composition
Common Stock $.001 Par, 01/11, 50M auth., 36,853,000 issd. less 1,236,000 shs. in Treas. @ $292K. Insiders & strategic holders own 64.79%. Public Offering 9/85, 40M Units (1 sh. com. + 3 warrants) @ $.01 by the Company. 02/07, Name changedfrom Champions Sports Inc.08/15, 1-for-12 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 619
855 N. Wolfe Street
BALTIMORE
MARYLAND 21205
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com